Building genomic surveillance capacity in low and middle-income countries
Growing a global network of labs with AMR expertise
Generating actionable data to identify high-risk bacterial pathogens, and support public health programmes
We are targeting the most relevant pathogen-antibiotic combinations at each collaborating surveillance Unit; analysing pathogen sequence data, basic anonymised patient information, and information about how samples were collected. Understanding the changing profile of antimicrobial resistance enables public health programmes to respond accordingly, locally, regionally and ultimately nationally
Laboratory Infrastructure: We will implement whole genome sequencing (WGS) of pathogens at national unit laboratories in LMICs. Each national unit represents a network of sentinel sites involved in surveillance of AMR.
Training: Together with the Wellcome Genome Campus Advanved Courses programme, we’re providing training workshops and materials to support local training and knowledge transfer
Data Infrastructure: We are Building expertise in data analysis and interpretation through easy-to- use tools developed at the Centre for Genomic Pathogen Surveillance to enable each national unit to expand local research agendas.
Linking genomic and epidemiological surveillance data at a national level will enable more targeted interventions for infection control, to identify and manage AMR outbreaks once they have occurred and help prevent further spread
Genomic surveillance of key pathogens will be undertaken to enable better understanding of the population and evolutionary biology of target organisms. Focus will be made on local priorities with respect to current AMR targets. Phenotypic surveillance combined with genomic surveillance will provide routes to intervention.
Data from all national units and sentinel sites will be available to the international community through open platforms (e.g., WGSA and Microreact) and public sequence databases (e.g., ENA), and will feed into the global monitoring of pathogens and AMR.
Learn more about the GHRU, who we are, and what we’re doing to tackle antimicrobial resistance
To achieve global surveillance, we’ve established units in the UK, Colombia, India, Nigeria and The Philippines.
Professor Ravikumar has established and leads a network of more than 125 laboratories and hospitals across India, and developed molecular methods to identify and type S. pneumoniae and culture clinical samples. He is Chairman of Infection Control Committee, a core member of The Sentinel Surveillance Programme and an Advisory Board member on antimicrobial resistance.
Dr Carlos is a paediatric infectious disease specialist, responsible for the expansion of sentinel sites across all 17 regions of the Philippines. Celia has been president of the Paediatric Infectious Disease Society of the Philippines, founded the Alliance for Prudent Use of Antibiotics (APUA), and represented the Philippines to the World Health Organization (WHO) Global Salmonella Surveillance and WHO Gonococcal Resistance Surveillance Program in the Western Pacific.
Professor Okeke’s research is focused on antimicrobial resistance, molecular epidemiology and pathogenesis, particularly of E. coli and other enteric bacteria. She also researches the applications and uptake of microbiology, particularly in African settings, and advocates antimicrobial resistance containment. Iruka sits on the Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) advisory board of the Wellcome Trust. She also currently serves as a drug resistance consultant to the Nigeria Centre for Disease Control, Africa CDC, WHO and other organizations.
Dr Donado-Godoy is a public health veterinarian and epidemiologist, who established Colombia’s Program for Integrated Surveillance of Antimicrobial Resistance (COIPARS), an international public-private network for establishing baselines for antimicrobial resistance of zoonotic bacteria. She works closely with the Pan American Health Organization of the WHO.
Dr. John Stelling is an infectious disease specialist in Boston, Massachusetts. He received his medical degree from Johns Hopkins Medical School and has a Master's in Public Health from (MIT) Massachussett's Institute of Technology. Dr. Stelling has been in practice for 29 years.
Senior Group Leader at Big Data Institute, University of Oxford. Within CGPS, broad aims are to provide data and tools for local, national and international utility focused on antimicrobial resistance and genomic surveillance. We are addressing the utility of large-scale structured pathogen surveys to provide contextual WGS datasets and population structure. Key aims are to enable the identification of high risk clones of public health importance, their risk assessment (eg resistance, virulence and transmissibility) and ultimately management.
If you are interested in joining our network of sentinel sites for genomic surveillance of AMR please contact us as per the details below.
NIHR Global Health Research Unit
Centre for Genomic Pathogen Surveillance
Wellcome Genome Campus
CB10 1SA UK